| Russell, Nigel H., Othman, Jad, Cumming, Oliver Sebastian, Thomas, Abin  ORCID: https://orcid.org/0000-0002-8283-6762, Tedjaseputra, Aditya, Potter, Nicola, Jovanovic, Jelena, Gilkes, Amanda Frances, Batten, Leona, Canham, Joanna  ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Runglall, Manohursingh, Aucken, Phoebe, Kottaridis, Panagiotis, Cavenagh, James Durrell, Arnold, Claire, Freeman, Sylvie D., Dennis, Mike, Knapper, Steven and Dillon, Richard James
      2025.
      
      Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3 mutated AML.
      Blood Advances
      
      
      
      , bloodadvances.2025017244.
      10.1182/bloodadvances.2025017244   | 
|   | 
| Russell, Nigel, Cumming, Oliver, Othman, Jad, Dillon, Richard, Potter, Nicola, Wilhelm-Benartzi, Charlotte  ORCID: https://orcid.org/0000-0003-4927-6158, Jovanovic, Jelena, Gilkes, Amanda, Batten, Leona, Canham, Joanna  ORCID: https://orcid.org/0000-0003-3482-0990, Laura Hinson, Emily, Kottaridis, Panagiotis, Cavenagh, Jamie, Arnold, Claire, Dennis, Mike and Knapper, Steven  ORCID: https://orcid.org/0000-0002-6405-4441
      2023.
      
      P484: Gemtuzumab-based induction chemotherapy combined with midostaurin for FLT3 mutated AML. Updated toxicity and interim survival analysis from the NCRI AML19v2 "Midotarg" Pilot Trial.
      HemaSphere
      7
      
        (S3)
      
      
      , e13145db.
      10.1097/01.HS9.0000968844.13145.db   | 
|   | 

 
							

![[up]](/style/images/multi_up.png) Up a level
 Up a level